查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1661097

特發性肺纖維化治療市場報告，按藥物類別（MAPK 抑制劑、酪胺酸抑制劑、自分泌運動因子抑制劑）、最終用戶（醫院、長期照護機構等）和地區分類，2025 年至 2033 年

Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-term Care Facilities, and Others), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2024IMARC Group全球特發性肺纖維化治療市場規模達 41.037 億美元。

特發性肺纖維化 (IPF) 是指一種進行性和不可逆的纖維化間質性肺炎，直接影響肺功能。其特徵是肺部內部形成疤痕組織，從邊緣開始向中心發展，導致呼吸困難和身體各部位供氧不足。透過胸部影像學檢查、肺活體組織切片、肺功能測試和抗體測試可以進行診斷。兩種最常用的抗纖維化療法包括尼達尼布和吡非尼酮類藥物，可改善肺功能並最大限度地降低急性呼吸系統惡化的風險。它們通常與氧氣療法和安寧療護相結合，以提供舒適感並改善患者的康復。

纖維化疾病盛行率的不斷上升以及全球老年人口的不斷增加是推動市場成長的關鍵因素之一。此外，生活方式的改變和香菸等尼古丁產品的消費增加也推動了市場的成長。此外，吸煙被認為是導致 IPF 的最常見原因之一。同時，大眾對特發性肺纖維化 (IPF) 有效管理策略的健康意識不斷增強，也有利於市場的成長。此外，新型藥物的出現以及特發性肺纖維化（IPF）診斷和治療方法的進步也起到了其他促進生長的因素的作用。這一因素，加上廣泛的研發活動和醫療保健基礎設施的改善，代表了預計將進一步推動市場發展的其他一些因素。

本報告回答的關鍵問題：

  • 全球特發性肺纖維化治療市場迄今表現如何？
  • COVID-19 對全球特發性肺纖維化治療市場有何影響？
  • 主要的區域市場有哪些？
  • 根據藥品類別，市場是如何分類的？
  • 根據最終用戶，市場分佈如何？
  • 該產業的價值鏈分為哪些階段？
  • 該行業的關鍵促進因素和挑戰是什麼？
  • 全球特發性肺纖維化治療市場的結構是如何的？
  • 該產業的競爭程度如何？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球特發性肺纖維化治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依藥物類別

  • MAPK 抑制劑
    • 市場趨勢
    • 市場預測
  • 酪胺酸抑制劑
    • 市場趨勢
    • 市場預測
  • 自分泌運動因子抑制劑
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：按最終用戶

  • 醫院
    • 市場趨勢
    • 市場預測
  • 長期照護機構
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場區隔：依國家
    • 市場預測

第 9 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 10 章：價值鏈分析

第 11 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 12 章：價格分析

第 13 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AdAlta Pty Ltd.
    • Angion Biomedica Corp.
    • Boehringer Ingelheim International GmbH (CH Boehringer Sohn AG & Co. KG)
    • Bristol-Myers Squibb Company
    • Cipla Inc.
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • Fibrogen Inc.
    • Galapagos NV
    • Liminal BioSciences Inc.
    • Medicinova Inc.
    • Merck & Co. Inc.
    • Novartis AG
    • Vectura Group Plc
Product Code: SR112025A2507

The global idiopathic pulmonary fibrosis treatment market size reached USD 4,103.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 7,315.8 Million by 2033, exhibiting a growth rate (CAGR) of 6.3% during 2025-2033.

Idiopathic pulmonary fibrosis (IPF) refers to a progressive and irreversible fibrosing interstitial pneumonia that directly impacts the functioning of the lungs. It is characterized by the formation of scar tissue within the lungs that starts at the edges and progresses toward the center, thus causing difficulties in breathing and insufficient delivery of oxygen to the body parts. It is diagnosed through chest imaging studies, lung biopsies, pulmonary function tests and antibody tests. Two of the most commonly used antifibrotic therapy includes nintedanib and pirfenidone-based drugs, which improves lung functioning and minimizes the risks of acute respiratory deterioration. They are often coupled with oxygen therapy and palliative care to provide comfort and improve the recovery of the patient.

The increasing prevalence of fibrotic diseases, along with the rising geriatric population across the globe, is one of the key factors driving the growth of the market. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products, such as cigarettes, is providing a thrust to the market growth. Moreover, smoking tobacco and cigarettes is considered as one of the most common causes for the development of IPF. In line with this, increasing health consciousness among the masses regarding the effective management strategies of IPF is also favoring the growth of the market. Additionally, the advent of novel medicines and advancements in the IPF diagnostic and treatment methods, are acting as other growth-inducing factors. This, along with extensive research and development (R&D) activities and improvements in the healthcare infrastructure, represents some of the other factors anticipated to drive the market further.

Key Market Segmentation:

Breakup by Drug Class:

  • MAPK Inhibitors
  • Tyrosine Inhibitors
  • Autotaxin Inhibitors

Breakup by End User:

  • Hospitals
  • Long-term Care Facilities
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being AdAlta Pty Ltd., Angion Biomedica Corp., Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG), Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Roche Holding AG), Fibrogen Inc., Galapagos NV, Liminal BioSciences Inc., Medicinova Inc., Merck & Co. Inc., Novartis AG and Vectura Group Plc.

Key Questions Answered in This Report:

  • How has the global idiopathic pulmonary fibrosis treatment market performed so far and how will it perform in the coming years ?
  • What has been the impact of COVID-19 on the global idiopathic pulmonary fibrosis treatment market ?
  • What are the key regional markets ?
  • What is the breakup of the market based on the drug class ?
  • What is the breakup of the market based on the end user ?
  • What are the various stages in the value chain of the industry ?
  • What are the key driving factors and challenges in the industry ?
  • What is the structure of the global idiopathic pulmonary fibrosis treatment market and who are the key players ?
  • What is the degree of competition in the industry ?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Idiopathic Pulmonary Fibrosis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 MAPK Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Tyrosine Inhibitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Autotaxin Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Long-term Care Facilities
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AdAlta Pty Ltd.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
    • 13.3.2 Angion Biomedica Corp.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Bristol-Myers Squibb Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Cipla Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 SWOT Analysis
    • 13.3.7 Fibrogen Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Galapagos NV
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Liminal BioSciences Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
    • 13.3.10 Medicinova Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Merck & Co. Inc.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Novartis AG
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
    • 13.3.13 Vectura Group Plc
      • 13.3.13.1 Company Overview
      • 13.3.13.2 Product Portfolio
      • 13.3.13.3 Financials
      • 13.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2024
  • Figure 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2024
  • Figure 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 7: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: North America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: North America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Canada: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Canada: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: China: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: China: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Australia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Australia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Europe: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Germany: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Germany: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: France: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: France: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Italy: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Italy: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Spain: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Spain: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Russia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Russia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
  • Figure 68: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
  • Figure 69: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market Structure
  • Table 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players